$80.89
1.53%
Nasdaq, Sep 05, 10:00 pm CET
ISIN
US6707031075
Symbol
NUVL

Nuvalent Inc - Ordinary Shares - Class A Stock price

$80.89
+2.27 2.89% 1M
+8.90 12.36% 6M
+2.61 3.33% YTD
-4.07 4.79% 1Y
+64.14 382.93% 3Y
+62.14 331.41% 5Y
+62.14 331.41% 10Y
+62.14 331.41% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
+1.22 1.53%
ISIN
US6707031075
Symbol
NUVL
Industry

Key metrics

Basic
Market capitalization
$5.8b
Enterprise Value
$4.8b
Net debt
positive
Cash
$1.0b
Shares outstanding
72.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.2
Financial Health
Equity Ratio
93.7%
Return on Equity
-24.4%
ROCE
-37.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-379.0m
EBIT
$-362.0m | $-422.6m
Net Income
$-343.3m | $-380.0m
Free Cash Flow
$-239.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-78.4% | -50.7%
Net Income
-97.8% | -45.7%
Free Cash Flow
-83.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.8
FCF per Share
$-3.3
Short interest
17.9%
Employees
200
Rev per Employee
$0.0
Show more

Is Nuvalent Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Nuvalent Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

Buy
95%
Hold
5%

Financial data from Nuvalent Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 77 77
54% 54%
-
- Research and Development Expense 285 285
86% 86%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -362 -362
78% 78%
-
Net Profit -343 -343
98% 98%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nuvalent Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvalent Inc - Ordinary Shares - Class A Stock News

Neutral
PRNewsWire
one day ago
Rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC initiated under FDA's RTOR program, with completion on track for the third quarter of 2025 CAMBRIDGE, Mass. , Sept. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer...
Neutral
PRNewsWire
11 days ago
CAMBRIDGE, Mass. , Aug. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Neutral
PRNewsWire
26 days ago
CAMBRIDGE, Mass. , Aug. 13, 2025 /PRNewswire/ --  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-sm...
More Nuvalent Inc - Ordinary Shares - Class A News

Company Profile

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Head office United States
CEO James Porter
Employees 200
Founded 2017
Website www.nuvalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today